A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

Eric Snoeck, Pascal Chanu, Marc Lavielle, +7

Clinical Pharmacology & Therapeutics

Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid

Craig R. Rayner, Pascal Chanu, Ronald Gieschke, +2

The Journal of Clinical Pharmacology

Oral OseltamivirPharmacokinetic ModelingMedicineOral ProbenecidAntiviral Drug Development +10

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Colby S. Shemesh, Pascal Chanu, Kris M. Jamsen, +10

Journal for ImmunoTherapy of Cancer

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma

Dan Lü, Tong Lu, Leonid Gibiansky, +11

CPT Pharmacometrics & Systems Pharmacology

ImmunologyUnconjugated MmaePharmacotherapyImmunotherapyPhysiologically-based Pharmacokinetic Modeling +17

Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma

Tong Lu, Leonid Gibiansky, Xiaobin Li, +9

Leukemia & lymphoma/Leukemia and lymphoma

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA‐Naïve and ESA‐Treated Chronic Kidney Disease Patients With Renal Anemia

Pascal Chanu, Ronald Gieschke, Jean‐Eric Charoin, +2

The Journal of Clinical Pharmacology

HemodialysisTranslational MedicinePopulation Pharmacokinetic/pharmacodynamic ModelPharmacokinetic ModelingRenal Function +13

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Enriqueta Felip, Mauricio Burotto, Zanete Zvirbule, +12

Clinical Pharmacology in Drug Development

Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150

René Bruno, Mathilde Marchand, Kenta Yoshida, +12

Clinical Cancer Research

Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer

René Bruno, Lars Lindbom, Franziska Schaedeli Stark, +4

CPT Pharmacometrics & Systems Pharmacology

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB

Samira Jamalian, Michael Dolton, Pascal Chanu, +8

CPT Pharmacometrics & Systems Pharmacology

AgingDisease ProgressionNeurochemical BiomarkersLongitudinal NeuroimagingGeriatric Neurology +20